The latest price target for Mirum Pharmaceuticals (NASDAQ:MIRM) was reported by Cantor Fitzgerald on August 8, 2024. The analyst firm set a price target for $60.00 expecting MIRM to rise to within 12 months (a possible 45.88% upside). 44 analyst firms have reported ratings in the last year.

The latest analyst rating for Mirum Pharmaceuticals (NASDAQ:MIRM) was provided by Cantor Fitzgerald, and Mirum Pharmaceuticals maintained their overweight rating.

There is no last upgrade for Mirum Pharmaceuticals

There is no last downgrade for Mirum Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mirum Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mirum Pharmaceuticals was filed on August 8, 2024 so you should expect the next rating to be made available sometime around August 8, 2025.

While ratings are subjective and will change, the latest Mirum Pharmaceuticals (MIRM) rating was a maintained with a price target of $50.00 to $60.00. The current price Mirum Pharmaceuticals (MIRM) is trading at is $41.13, which is out of the analyst’s predicted range.